8
Treatment
MET Second-line
Recommendation 10.1
➤ Patients with MET abnormalities other than exon 14 skipping
mutations, a performance status of 0–2, or those previously treated
with MET-targeted therapy, clinicians should offer standard therapy
based on the ASCO/OH non-driver mutations guideline (Moderate
recommendation; IC-L).
Recommendation 10.2
➤ For patients with a MET exon 14 skipping mutation, a performance
status of 0–2, who have previously received or been ineligible for
first-line chemotherapy with or without immunotherapy, clinicians
may offer MET-targeted therapy with capmatinib or tepotinib
(Moderate recommendation; IC-L).
RET Rearrangement First-line
Recommendation 11.1
➤ For patients with a RET rearrangement, a performance status of 0–2,
and previously untreated NSCLC, clinicians may offer selpercatinib or
pralsetinib (Weak recommendation; IC-L).
Recommendation 11.2
➤ For patients with a RET rearrangement, a performance status of 0–2,
previously untreated NSCLC, clinicians may offer standard therapy
based on the ASCO/OH non-driver mutation guideline (Moderate
recommendation; IC-L).
RET Rearrangement Second-line
Recommendation 12.1
➤ For patients with RET rearrangement who have had previous RET-
targeted therapy, clinicians may offer treatment per the non-driver
mutation guideline (Moderate recommendation; IC-L).
Recommendation 12.2
➤ For patients with RET rearrangement, if RET-targeted therapy
was not given in the first-line setting, clinicians may offer
selpercatinib (Moderate recommendation; IC-L) or pralestinib (Weak
recommendation; IC-L).
